Aikido Pharma rises as Wainwright starts with 'buy'

Dominari Holdings

11/10/2021 14:26

** Shares of cancer drug developer  AIKI.O  rise 4% to
$0.908 premarket; set to gain for a fourth straight session 
    ** Brokerage H.C. Wainwright starts with "buy" rating and PT
of $2
    ** Wainwright sees promise in co's drugs for prostate and
pancreatic cancers, as well as its leukemia treatment
    ** Sees completion of early-stage trial of co's prostate
cancer drug, CONV 01-α, as a catalyst in early 2022
    ** Stock down 0.4% this year, as of last close

 (Reporting by Susan Mathew)
 ((susan.mathew@thomsonreuters.com))